Last reviewed · How we verify
SUBLIVAC® Birch Prospective, Randomized, Open, Blinded Endpoint (PROBE) Study
Objective of the study is to show, on an exploratory basis, that treatment with SUBLIVAC Birch is also effective compared to treatment with Staloral Birch by means of reduction in allergic symptoms during nasal provocation in subjects suffering from IgE mediated allergic complaints triggered by birch pollen.
Details
| Lead sponsor | HAL Allergy |
|---|---|
| Phase | Phase 2 |
| Status | COMPLETED |
| Enrolment | 74 |
| Start date | 2009-07 |
Conditions
- Seasonal Rhinitis and/or Rhinoconjunctivitis
- Birch Pollen Allergy
Interventions
- sublingual immunotherapy
Primary outcomes
- Difference in change of the titrated nasal provocation test (TNPT) between the two treatment groups — 16-20 weeks of treatment
Countries
Germany